IP Library Granted Patent US 11,738,070
Granted Patent B2
US 11,738,070 · App. 17/095,673 · Granted Aug 29, 2023

Methods and compositions for improved cognition

Inventor: Dena Dubal (Oakland, CA)
Assignee: The Regents of the University of California
A61K38/47A61P25/28C12N9/2402C12Y302/01031A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,738,070
App. No.
17/095,673
Granted
Aug 29, 2023
Kind
B2
Abstract

Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.

Claims (15)

1. A method of treating cognitive decline in an individual having a neurodegenerative disease or traumatic brain injury (TBI), comprising administering systemically to the individual an effective amount of a recombinant polypeptide comprising the amino acid sequence having at least 95% identity to the sequence of amino acids 34-979 of SEQ ID NO:1, with the proviso that the polypeptide is not a FGF fusion protein.

2. The method of claim 1 , wherein the individual's neurodegenerative disease is Alzheimer's disease, Parkinson's disease, frontotemporal dementia, mild cognitive impairment, or Lewy body dementia.

3. The method of claim 1 , wherein the amino acid sequence is at least 99% identical to amino acids 34-979 of SEQ ID NO:1.

4. The method of claim 1 , wherein the amino acid sequence comprises amino acids 34-979 of SEQ ID NO:1.

5. The method of claim 1 , comprising:

determining cognitive function in the subject before administration of the polypeptide,

determining cognitive function in the subject following systemic administration of the polypeptide, and

comparing the cognitive function in the subject before administration of the klotho to the cognitive function of the subject following administration of the polypeptide.

6. The method of claim 1 , wherein the polypeptide is administered to the subject intravenously.

7. The method of claim 2 , wherein the individual's neurodegenerative disease is Alzheimer's Disease.

8. The method of claim 2 , wherein the individual's neurodegenerative disease is Parkinson's Disease.

9. The method of claim 2 , wherein the individual's neurodegenerative disease is frontotemporal dementia.

10. The method of claim 2 , wherein the individual's neurodegenerative disease is mild cognitive impairment.

11. The method of claim 2 , wherein the individual's neurodegenerative disease is Lewy body dementia.

12. The method of claim 1 , wherein the individual has traumatic brain injury.

Continuity (4)
Continuation 16751108 · Jan 23, 2020
Continuation 15548306
Provisional Application 62113300 · Feb 6, 2015
Related Publication 20210069305A1 · Mar 11, 2021
Cited By (1)
US 12,239,694